Please assess the completion status of the following clinical trial:

Trial Title: The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female of 50-85 years of age~2. Subjects with recent COVID-19 diagnosis (within 72 hours), that are symptomatic (fever, cough, SOB, weakness, or other flu-like symptoms).~3. Agrees to comply with study procedures (diary, oximeter readings, telephone follow up).~4. Has given voluntary, written, informed consent to participate in the study.~5. Identifies as African American or Hispanic Origin~6. Patients must have at least 1 risk factor (history of hypertension (BP\> 140/99) CHF, angina, prior MI, coronary angiography with one significantly occluded vessel, diabetes mellitus, obesity, or smoking, (for at least 5 years).~Exclusion Criteria:~1. Females who are pregnant, breastfeeding or planning to become pregnant during the course of the study.~2. Patients unresponsive or unable to take anything by mouth (NPO).~3. Individuals who are cognitively impaired and/or who are unable to give informed consent.~4. Blood pressure below 110 mmHg systolic and 60 mmHg diastolic on entry into study.~5. History of syncope or other symptoms of orthostatic hypotension.~6. History of methemoglobinemia.~7. Severe case of G6PD deficiency

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Nitric Oxide (Type: ACTIVE_COMPARATOR): Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo of Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days

Based on this trial design, predict the completion outcome and termination type (if applicable).